Cambrex Co. (CBM) Given Average Rating of “Buy” by Brokerages

Cambrex Co. (NYSE:CBM) has been given an average recommendation of “Buy” by the six analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $66.50.

Several brokerages recently issued reports on CBM. Zacks Investment Research upgraded shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price for the company in a research note on Wednesday, August 8th. ValuEngine downgraded shares of Cambrex from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 7th.

NYSE:CBM traded up $1.75 during mid-day trading on Friday, hitting $63.20. The stock had a trading volume of 339,400 shares, compared to its average volume of 345,216. Cambrex has a twelve month low of $42.55 and a twelve month high of $67.75. The company has a market capitalization of $2.04 billion, a P/E ratio of 19.65, a price-to-earnings-growth ratio of 1.45 and a beta of 2.40.

Cambrex (NYSE:CBM) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.05. Cambrex had a net margin of 20.75% and a return on equity of 22.32%. The business had revenue of $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. During the same period last year, the business posted $0.76 EPS. Cambrex’s revenue was up 13.0% on a year-over-year basis. equities research analysts anticipate that Cambrex will post 2.82 earnings per share for the current year.

In other Cambrex news, CEO Steven M. Klosk sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $45.64, for a total transaction of $2,510,200.00. Following the completion of the sale, the chief executive officer now directly owns 218,328 shares in the company, valued at $9,964,489.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ilan Kaufthal sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $62.38, for a total transaction of $343,090.00. Following the sale, the director now owns 54,084 shares of the company’s stock, valued at $3,373,759.92. The disclosure for this sale can be found here. Insiders have sold 324,250 shares of company stock valued at $18,740,653 over the last 90 days. Company insiders own 2.42% of the company’s stock.

A number of hedge funds have recently modified their holdings of CBM. Itau Unibanco Holding S.A. acquired a new stake in Cambrex during the second quarter worth approximately $178,000. Zebra Capital Management LLC acquired a new stake in Cambrex during the second quarter worth approximately $200,000. Shaker Investments LLC OH acquired a new stake in Cambrex during the first quarter worth approximately $209,000. D.A. Davidson & CO. acquired a new stake in Cambrex during the second quarter worth approximately $216,000. Finally, Stevens Capital Management LP acquired a new stake in Cambrex during the first quarter worth approximately $217,000.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Read More: Book Value Per Share – BVPS

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply